All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View psoriasis and psoriatic arthritis content recommended for you
Targeting the IL-23/IL-17 axis in psoriatic disease
Do you know... Which cytokine is primarily responsible for driving the differentiation of Th17 cells, leading to increased IL-17 production and subsequent keratinocyte activation in psoriasis?
Psoriasis is a chronic autoimmune inflammatory disease, involving both innate and adaptive immune responses. A key driver of its pathogenesis is the interleukin (IL)-23/IL-17 axis, which plays a central role in driving the inflammatory cascade. Targeting this pathway has significantly transformed the treatment landscape, offering effective options for both plaque psoriasis and psoriatic arthritis.
Below, we summarize the immunopathogenic role of the IL-23/IL-17 axis and its relevance as a therapeutic target in psoriatic disease.
This educational resource is independently supported by UCB. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
